Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18183405 | 0.98 | MEN1 (0.32) | MEN1KMT2AGFER | |
| SCHEMBL18603274 | 0.98 | MEN1 (0.32) | MEN1KMT2AGFER | |
| SCHEMBL18183404 | 0.92 | MEN1 (0.32) | MEN1KMT2A | |
| Mipimazole SCHEMBL2734172 | 0.86 | — | — | |
| Mipimazole SCHEMBL18183409 | 0.84 | MEN1 (0.38) | MEN1KMT2A | |
| Mipimazole SCHEMBL18603253 | 0.80 | MEN1 (0.41) | MEN1KMT2A | |
| SCHEMBL1106524 | 0.76 | SMN1; SMN2 (0.37) | JAK2 | |
| SCHEMBL20204697 | 0.74 | JAK2 (0.30) | JAK2 | |
| SCHEMBL25758668 | 0.74 | JAK2 (0.30) | JAK2 | |
| SCHEMBL10797718 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153907-A1 | DOUBLE DYNAMIC POLYMERS | UNIVERSITÉ DE STRASBOURG (FR) | 2022-05-19 | — | — | US | disclosed |
| US-20180009798-A1 | Inhibitors of Beta-Hydroxylase for Treatment of Cancer | MIDWESTERN UNIVERSITY | 2018-01-11 | — | — | US | disclosed |
| EP-1142887-B1 | 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents | PARKE DAVIS & CO (US) | 2004-04-07 | — | — | EP | disclosed |
| EP-0729463-B1 | 5,6-DIHYDROPYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS | PARKE DAVIS & CO (US) | 2002-05-22 | — | — | EP | disclosed |
| EP-1142887-A1 | 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents | PARKE, DAVIS & COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| US-5936128-A | BENZENETHIOL COMPOUNDS AS INTERMEDIATES; BACTERICIDES, VIRICIDES; HIV | WARNER-LAMBERT COMPANY (US) | 1999-08-10 | — | — | US | disclosed |
| US-5840751-A | ADMINISTERING IN THE TREATMENT OF INFECTION OR DISEASE CAUSED BY A RETROVIRUS | WARNER-LAMBERT COMPANY (US) | 1998-11-24 | — | — | US | disclosed |
| US-5789440-A | 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents | WARNER-LAMBERT COMPANY (US) | 1998-08-04 | — | — | US | disclosed |
| EP-0729464-A1 | 5,6-DIHYDROPYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS | PARKE, DAVIS & COMPANY (US) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995014012-A1 | 5,6-DIHYDROPYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS | PARKE, DAVIS & COMPANY (US) | 1995-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153907-A1 | DOUBLE DYNAMIC POLYMERS | PCNA, DCLRE1A, MRE11 | MEN1 2958/4885KMT2A 1321/4885GFER 496/4885 |
| US-20180009798-A1 | Inhibitors of Beta-Hydroxylase for Treatment of Cancer | ASPH, CYP46A1, ALDH7A1 | MEN1 4462/4885KMT2A 949/4885GFER 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.